A new study found that iron supplements are safe for children with HIV in Uganda, as they improve hemoglobin levels without ...

Bilirubin, the primary breakdown product of hemoproteins, particularly hemoglobin, plays a key role in the diagnosis, prognosis, and monitoring of liver diseases. In acute liver diseases, such as ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Bilirubin, the primary breakdown product of hemoproteins, particularly hemoglobin, plays a key role in the diagnosis, prognosis, and monitoring of liver diseases. In acute liver diseases, such as ...

The condition is caused by a mutation in the hemoglobin gene, which produces an abnormal form of hemoglobin known as hemoglobin S. This abnormal protein alters the shape of red blood cells, making ...

William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating today. Sami Corwin’s rating is ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

Diabetes might seem overwhelming, but it doesn’t have to be. In this post, we break... The post What is Diabetes and How To ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

BEAM-101 is an investigational treatment for SCD that uses a form of gene editing known as base editing to modify the promotor regions of the HBG1/2 genes, enabling BCL11A genes to produce fetal ...